321 related articles for article (PubMed ID: 19663767)
1. Anti-EGFR therapy in colorectal cancer: how to choose the right patient.
Meriggi F; Di Biasi B; Abeni C; Zaniboni A
Curr Drug Targets; 2009 Oct; 10(10):1033-40. PubMed ID: 19663767
[TBL] [Abstract][Full Text] [Related]
2. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.
Mancl EE; Kolesar JM; Vermeulen LC
Am J Health Syst Pharm; 2009 Dec; 66(23):2105-12. PubMed ID: 19923311
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
6. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
[TBL] [Abstract][Full Text] [Related]
7. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Misale S; Yaeger R; Hobor S; Scala E; Janakiraman M; Liska D; Valtorta E; Schiavo R; Buscarino M; Siravegna G; Bencardino K; Cercek A; Chen CT; Veronese S; Zanon C; Sartore-Bianchi A; Gambacorta M; Gallicchio M; Vakiani E; Boscaro V; Medico E; Weiser M; Siena S; Di Nicolantonio F; Solit D; Bardelli A
Nature; 2012 Jun; 486(7404):532-6. PubMed ID: 22722830
[TBL] [Abstract][Full Text] [Related]
8. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
[TBL] [Abstract][Full Text] [Related]
9. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
12. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Lièvre A; Laurent-Puig P
Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing.
Ashraf N; Kothari N; Kim R
J Natl Compr Canc Netw; 2014 Oct; 12(10):1433-42. PubMed ID: 25313182
[TBL] [Abstract][Full Text] [Related]
15.
van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
[TBL] [Abstract][Full Text] [Related]
16. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Fabian P; Berkovcová J
Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
[TBL] [Abstract][Full Text] [Related]
17. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.
Yoshida M; Shimura T; Sato M; Ebi M; Nakazawa T; Takeyama H; Joh T
J Cancer Res Clin Oncol; 2013 Mar; 139(3):367-78. PubMed ID: 23099994
[TBL] [Abstract][Full Text] [Related]
18. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
19. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
20. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]